Immune marker expression of irradiated mesothelioma cell lines.
MHC
PD-L1
immune checkpoint inhibition
mesothelioma
radiotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
08
2022
accepted:
03
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Though immune checkpoint inhibition has recently shown encouraging clinical efficacy in mesothelioma, most patients do not respond. Combining immune checkpoint inhibition with radiotherapy presents an attractive option for improving treatment responses owing to the various immunomodulatory effects of radiation on tumors. However, the ideal dosing and scheduling of combined treatment remains elusive, as it is poorly studied in mesothelioma. The present study characterizes the dose- and time-dependent changes to expression of various immune markers and cytokines important to antitumor responses following irradiation of mesothelioma cell lines. Two murine (AB1, AE17) and two human (BYE, JU77) mesothelioma cell lines were treated with titrated gamma-radiation doses (1-8 Gy) and the expression of MHC class-I, MHC class-II and PD-L1 was measured over a series of post-irradiation timepoints (1-72 hours) by flow cytometry. Levels of cytokines IL-1α, IL-1β, IL-6, IL-10, IL-12p70, IL-17A, IL-23, IL-27, MCP-1, IFN-β, IFN-γ, TNF-α, and GM-CSF were measured by multiplex immunoassay in murine cell lines following 8 Gy radiation. Following irradiation, a dose-dependent upregulation of MHC-I and PD-L1 was observed on three of the four cell lines studied to varying extents. For all cell lines, the increase in marker expression was most pronounced 72 hours after radiation. At this timepoint, increases in levels of cytokines IFN-β, MCP-1 and IL-6 were observed following irradiation with 8 Gy in AB1 but not AE17, reflecting patterns in marker expression. Overall, this study establishes the dose- and time-dependent changes in immune marker expression of commonly studied mesothelioma cell lines following radiation and will inform future study into optimal dosing and scheduling of combined radiotherapy and immune checkpoint inhibition for mesothelioma.
Sections du résumé
Background
UNASSIGNED
Though immune checkpoint inhibition has recently shown encouraging clinical efficacy in mesothelioma, most patients do not respond. Combining immune checkpoint inhibition with radiotherapy presents an attractive option for improving treatment responses owing to the various immunomodulatory effects of radiation on tumors. However, the ideal dosing and scheduling of combined treatment remains elusive, as it is poorly studied in mesothelioma. The present study characterizes the dose- and time-dependent changes to expression of various immune markers and cytokines important to antitumor responses following irradiation of mesothelioma cell lines.
Methods
UNASSIGNED
Two murine (AB1, AE17) and two human (BYE, JU77) mesothelioma cell lines were treated with titrated gamma-radiation doses (1-8 Gy) and the expression of MHC class-I, MHC class-II and PD-L1 was measured over a series of post-irradiation timepoints (1-72 hours) by flow cytometry. Levels of cytokines IL-1α, IL-1β, IL-6, IL-10, IL-12p70, IL-17A, IL-23, IL-27, MCP-1, IFN-β, IFN-γ, TNF-α, and GM-CSF were measured by multiplex immunoassay in murine cell lines following 8 Gy radiation.
Results
UNASSIGNED
Following irradiation, a dose-dependent upregulation of MHC-I and PD-L1 was observed on three of the four cell lines studied to varying extents. For all cell lines, the increase in marker expression was most pronounced 72 hours after radiation. At this timepoint, increases in levels of cytokines IFN-β, MCP-1 and IL-6 were observed following irradiation with 8 Gy in AB1 but not AE17, reflecting patterns in marker expression.
Conclusions
UNASSIGNED
Overall, this study establishes the dose- and time-dependent changes in immune marker expression of commonly studied mesothelioma cell lines following radiation and will inform future study into optimal dosing and scheduling of combined radiotherapy and immune checkpoint inhibition for mesothelioma.
Identifiants
pubmed: 36387076
doi: 10.3389/fonc.2022.1020493
pmc: PMC9659742
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1020493Informations de copyright
Copyright © 2022 Chang, Keam, Hoang, Creaney, Gill, Nowak, Ebert and Cook.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Cancer Res. 2017 Sep 15;23(18):5502-5513
pubmed: 28606922
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
EMBO Mol Med. 2017 Feb;9(2):167-180
pubmed: 27932443
Lung Cancer. 2019 Jun;132:24-27
pubmed: 31097089
Front Oncol. 2020 Feb 21;10:187
pubmed: 32154179
Clin Transl Immunology. 2020 Sep 10;9(9):e1169
pubmed: 32994997
Oncol Lett. 2021 Jun;21(6):446
pubmed: 33868484
Int J Cancer. 1992 Dec 2;52(6):881-6
pubmed: 1459729
Front Immunol. 2016 Dec 22;7:610
pubmed: 28066420
Immunol Lett. 2017 Apr;184:7-14
pubmed: 28223102
Cancers (Basel). 2021 Aug 09;13(16):
pubmed: 34439164
Cancer Res. 2004 Nov 1;64(21):7985-94
pubmed: 15520206
Oncoimmunology. 2017 Aug 3;6(10):e1356153
pubmed: 29123967
Oncotarget. 2017 Jun 20;8(25):41242-41255
pubmed: 28465485
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
PLoS One. 2012;7(3):e32542
pubmed: 22396773
Oncotarget. 2017 Jul 12;8(46):80506-80520
pubmed: 29113321
J Clin Invest. 2019 Jul 15;129(8):3324-3338
pubmed: 31305264
J Thorac Oncol. 2017 Jul;12(7):1085-1097
pubmed: 28478231
Radiat Oncol. 2020 Nov 4;15(1):254
pubmed: 33148287
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Sci Transl Med. 2021 Apr 14;13(589):
pubmed: 33853932
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
Oncotarget. 2015 May 20;6(14):12468-80
pubmed: 25980578
Curr Opin Immunol. 2016 Apr;39:44-51
pubmed: 26796069
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Br J Cancer. 2020 Sep;123(7):1089-1100
pubmed: 32641865
Front Oncol. 2021 Dec 22;11:784081
pubmed: 35004305
J Med Imaging Radiat Oncol. 2022 Sep;66(6):881-895
pubmed: 35699321
Oncotarget. 2016 Feb 16;7(7):7913-24
pubmed: 26761210
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33827904
Transl Lung Cancer Res. 2017 Apr;6(2):212-219
pubmed: 28529903
Mil Med Res. 2018 Jun 30;5(1):20
pubmed: 29958545
Sci Rep. 2017 Sep 12;7(1):11373
pubmed: 28900290
J Exp Med. 2006 May 15;203(5):1259-71
pubmed: 16636135
Int J Cancer. 1991 Jan 21;47(2):285-90
pubmed: 1703129
Oncotarget. 2014 Jan 30;5(2):403-16
pubmed: 24480782